aptose
present
data
ash
annual
meeting
san
diego
toronto
globe
newswire
aptose
biosciences
aptose
nasdaq
apto
tsx
aps
company
developing
highly
differentiated
therapeutics
targeting
underlying
mechanisms
cancer
today
announced
early
clinical
data
along
certain
preclinical
data
oral
btk
cluster
selective
kinase
inhibitor
early
clinical
data
small
molecule
myc
inhibitor
presented
american
society
hematology
ash
annual
meeting
exposition
held
virtually
saturday
december
monday
december
abstracts
accepted
presentation
listed
viewed
online
ash
conference
website
note
presentations
include
additional
data
found
abstracts
poster
presentation
details
abstract
phase
b
dose
escalation
study
myc
repressor
patients
relapsed
refractory
aml
mds
poster
session
date
time
saturday
december
pt
session
name
acute
myeloid
leukemia
novel
therapy
excluding
transplantation
poster
abstract
pharmacologic
inhibition
b
kinases
induces
apoptosis
metabolic
reprogramming
aggressive
lymphoma
nhl
models
poster
session
date
time
saturday
december
pt
session
name
lymphoma
biologic
agents
poster
abstract
phase
b
dose
escalation
study
mutation
agnostic
btk
inhibitor
patients
relapsed
refractory
cll
sll
lymphomas
poster
session
date
time
sunday
december
pt
session
name
cll
therapy
excluding
transplantation
poster
ii
poster
abstracts
also
published
november
supplemental
issue
blood
ash
journal
available
online
aptose
aptose
biosciences
biotechnology
company
committed
developing
personalized
therapies
addressing
unmet
medical
needs
oncology
initial
focus
hematology
company
small
molecule
cancer
therapeutics
pipeline
includes
products
designed
provide
single
agent
efficacy
enhance
efficacy
therapies
regimens
without
overlapping
toxicities
company
two
investigational
products
hematologic
malignancies
oral
btk
kinase
inhibitor
phase
trial
patients
relapsed
refractory
b
cell
malignancies
including
chronic
lymphocytic
leukemia
cll
small
lymphocytic
lymphoma
sll
lymphoma
nhl
failed
intolerant
standard
therapies
separate
phase
trial
patients
relapsed
refractory
acute
myeloid
leukemia
aml
known
clinical
stage
agent
directly
targets
myc
oncogene
suppresses
expression
phase
clinical
trial
treatment
patients
relapsed
refractory
aml
high
risk
myelodysplastic
syndrome
mds
information
please
contact
